Literature DB >> 3710293

Enoxaparine low molecular weight heparin: its use in the prevention of deep venous thrombosis following total hip replacement.

A Planes, N Vochelle, J Ferru, D Przyrowski, J Clerc, M Fagola, M Planes.   

Abstract

UNLABELLED: The effect of Enoxaparin in the prevention of thromboembolism after total hip prosthesis has been controlled by phlebography. 228 consecutives patients were studied with 4 dose regimens: 60 mg once a day, 40 mg once a day, and 30 and 20 mg twice a day.
CONCLUSIONS: a total dose of 40 mg once a day or twice a day gives a rate of postoperative thrombosis of 8%.

Entities:  

Mesh：

Substances：

Year:  1986        PMID： 3710293     DOI： 10.1159/000215285

Source DB:  PubMed          Journal:  Haemostasis        ISSN： 0301-0147


  4 in total

Review 1.  New thrombolytics, anticoagulants, and platelet antagonists: the future of clinical practice.

Authors:  R C Becker
Journal:  J Thromb Thrombolysis       Date:  1999-04       Impact factor: 2.300

2.  Adjunctive Pharmacologic Treatment: Focus on the Development of Low Molecular Weight Heparins.

Authors: 
Journal:  J Thromb Thrombolysis       Date:  1997       Impact factor: 2.300

3.  Orthopaedic surgeons and thromboprophylaxis.

Authors:  M D Laverick; S A Croal; R A Mollan
Journal:  BMJ       Date:  1991-09-07

4.  Dose adjusted heparin treatment of deep venous thrombosis: a comparison of unfractionated and low molecular weight heparin.

Authors:  G F Handeland; U Abildgaard; H A Holm; K E Arnesen
Journal:  Eur J Clin Pharmacol       Date:  1990       Impact factor: 2.953
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.